Novo Nordisk slightly raises outlook as first-quarter profit beats forecast
Novo Nordisk slightly raises outlook as first-quarter profit beats forecast
ReutersWed, May 6, 2026 at 5:48 AM UTC
0
FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo
COPENHAGEN, May 6 (Reuters) - Novo Nordisk, the maker of weight-loss drug Wegovy, on Wednesday reported first-quarter revenue and adjusted operating profit above expectations and said its outlook for the year was slightly improved.
The Danish drugmaker is banking on demand for its new weight-loss pill as competition with U.S. rival Eli Lilly intensifies and investors demand proof that fast-rising volumes can offset a bruising obesity drug price war.
Novo said its adjusted operating profit was 32.86 billion Danish crowns ($5.16 billion) in the first quarter against a mean forecast of 28.74 billion according to a company-compiled poll.
Novo Nordisk said it now expects its adjusted sales and operating profit to decline this year by between 4% and 12% at constant exchange rates, compared with a previous range of minus 5% to minus 13% for both variables.
"The strong Wegovy performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit,” CEO Mike Doustdar said in a statement.
Advertisement
Novo has spent much of the past year on the defensive, grappling with setbacks including disappointing trial results for its next-generation obesity drug, weaker than expected sales and a share price slide that has erased more than $400 billion in market value since its 2024 peak.
Under Doustdar, who was appointed last year, Novo Nordisk is pinning a near-term recovery on its newly launched Wegovy pill, with margins already under pressure following last year's price cuts to the group's blockbuster weight-loss injection.
But Novo Nordisk's window as the only oral obesity pill on the U.S. market slammed shut in early April when Eli Lilly received FDA approval for its competing drug Foundayo, intensifying the battle with its main rival.
Novo Nordisk's share price is down almost 40% in the last 12 months, lagging Lilly's rise of around 18% over the same period, though the stock has been slowly tracking upwards since late March on rising hopes for its weight-loss pill.
Rival Lilly last week hiked its full-year profit and revenue forecasts as surging demand for its weight-loss and diabetes drugs helped offset lower prices across U.S. and international markets.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
Source: “AOL Money”
